Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Risk of Fetal Harm with Letrozole Use in Fertility Treatment: A Systematic Review and Meta-Analysis
29 Pages Posted: 13 Jul 2020
More...Abstract
Background: The aromatase inhibitor letrozole is increasingly recommended for ovulation induction, as it is more effective with fewer side-effects than other agents. But many clinicians are reluctant to use the drug for fertility treatment due to a strong-label warning against its use, which warns about congenital malformation risk to the fetus in women seeking pregnancy.
Objective: To determine the risks of congenital malformations and pregnancy loss with letrozole compared with clomiphene primarily, and against other fertility drugs and natural conception.
Methods: A systematic review and meta-analysis.
Findings: We included 45 studies (18 randomised trials; 20 comparative cohorts; 7 non-comparative cohorts). We did not observe a significant increase in congenital malformations with letrozole vs clomiphene in the randomised trials (Risk Difference RD 0.01, 95% CI -0.02, 0.03; I2 = 0%; 14 studies), and found a significant reduction in the cohort studies (RD -0.02, 95% CI -0.03, -0.004; I2 = 0%, 10 studies). The risks of pregnancy loss were not increased with letrozole vs clomiphene in the 14 randomised trials (RD -0.01, 95% CI -0.06, 0.04; I2 = 0%), and the risks were reduced in the six cohort studies (RD -0.09, 95% CI -0.17, -0.00; I2 = 68%). The GRADE quality of evidence was low to moderate for congenital malformations and pregnancy loss. We did not find any increased congenital malformation risk with letrozole vs gonadotrophins, natural conception or natural cycle assisted reproductive technology, but the number of studies was small.
Interpretation: There is no evidence that letrozole increases the risk of congenital fetal malformation or pregnancy loss than clomiphene, natural conception or other fertility agents to warrant warning against its use. Given its therapeutic benefits and lack of evidence of harm to the fetus, clinicians should consider letrozole as first-line agent for ovulation induction.
Funding Statement: None.
Declaration of Interests: None.
Keywords: Letrozole, Harm, Congenital malformations
Suggested Citation: Suggested Citation